Natco Pharma Ltd on Thursday said it has received approval from the US health regulator for its generic version of Everolimus ...

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous ...

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug ...

ANDA for Everolimus tablets for oral suspension (TFOS) of strengths 2mg, 3mg and 5mg, Natco Pharma said in a regulatory filing. (Image: Representational/Pixabay) The approval is for the Abbreviated ...

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous sclerosis complex ("TSC") for the treatment of subependymal giant cell ...

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...